GSK signs China distribution deal for hepatitis B drug
GSK has entered a distribution agreement with Sino Biopharmaceutical unit Chia Tai Tianqing to supply its experimental therapy bepirovirsen in mainland China. The deal supports GSK's goal of reaching 40 billion pounds in annual revenue by 2031 through expansion in the Chinese healthcare market.
Xurve View
Insights:
Xurve View
GSK PLC-SPON ADR signed a deal with Sino Biopharmaceutical to sell its experimental chronic hepatitis B therapy in China. The agreement targets a market where 75 million people live with the chronic viral infection. This partnership supports GSK's strategy to reach 40 billion pounds in annual revenue by 2031.
